Journal article icon

Journal article

Target trial emulation of effectiveness of COVID-19 mRNA vaccination during pregnancy in four European countries

Abstract:
Evidence on real-world effectiveness of COVID-19 vaccination during pregnancy remains limited. Using health data from the UK, Sweden, Spain, and Norway, we emulated two target trials to estimate vaccine effectiveness (VE) of mRNA COVID-19 vaccines administered during pregnancy against COVID-19 infection, hospitalisation, and admission to an Intensive Care Unit (ICU). The first trial compares initiation of a primary (two-dose) vaccination with unvaccinated, and the second compares the receipt of a first booster (third dose) with unboosted after primary vaccination. Pregnant women receiving a first or booster vaccination were matched weekly to comparable unexposed pregnant women. A total of 62,061 and 41,096 pregnant women were included in the first and second trial, respectively. Meta-analysis across the four databases showed a VE for primary vaccination of 26·2% (95% CI 16·2–35·1) against infection and 55·6% (95% CI 44·1–64·8) against hospitalisation. For boosters, the VE was 33.6% (95% CI 1·6–56·6) against infection and 34·1% (95% CI 0·6–56·4) against hospitalisation. ICU admission outcomes were too rare to analyse. In this work, we show that primary and first-booster mRNA vaccination during pregnancy is associated to a lower risk of COVID-19-related hospitalisation, while protection against infection is more modest and heterogeneous across databases. This study of over 100,000 pregnancies in four European countries found that both initial and booster COVID-19 mRNA vaccination during pregnancy were linked to lower risks of infection and related hospital admission.
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Publisher copy:
10.1038/s41467-026-78469-x

Authors

More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDORMS
Sub department:
Centre for Statistics in Medicine
Role:
Author
ORCID:
0009-0006-7948-3747


Publisher:
Nature Research
Journal:
Nature Communications More from this journal
Publication date:
2026-10-16
DOI:
EISSN:
2041-1723
ISSN:
2041-1723


Language:
English
Keywords:
Pubs id:
2487735
Local pid:
pubs:2487735
Source identifiers:
W7222519646
Deposit date:
2026-10-26
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads

Views and downloads will return soon






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP